Caladrius Biosciences (formerly known as Corniche Group, Phase III Medical, and NeoStem) is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s subsidiary, PCT, is a development and manufacturing partner exclusively focused on the cell therapy industry. PCT provides a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage, and distribution, as well as expert consulting and regulatory support. The company Caladrius Biosciences merged with Cend Therapeutics to form Lisata Therapeutics.